ATTO 488 Peptide Labeling

Pharmacokinetics (PK) and biodistribution studies are fundamental to understanding the absorption, distribution, metabolism, and excretion (ADME) of antibody therapeutics. These studies guide dosage design, administration frequency, and help predict the drug's efficacy and safety. Unlike small-molecule drugs, antibodies are large and structurally complex, exhibiting distinct in vivo transport mechanisms. As such, they cannot be accurately modeled using conventional small-molecule ADME frameworks. Antibodies typically distribute through receptor- or ligand-mediated pathways, and their biodistribution is influenced by various physiological factors, such as vascular permeability and lymphatic transport, leading to tissue-specific accumulation. Furthermore, antibodies are primarily catabolized via proteolytic degradation, and their half-life can vary significantly based on isotype, structural modifications, and inter-individual differences. These characteristics demand resource-intensive preclinical and clinical studies, often involving complex animal models and long study durations. Even with such efforts, patient variability continues to pose challenges in translating findings into clinical practice, creating significant obstacles for efficient antibody drug development.